The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

ALK-amplified circulating tumor cells as a surrogate marker for crizotinib benefit in ALK-rearranged non-small cell lung cancer patients.
 
Emma Pailler
No Relationships to Disclose
 
Jordi Remon
No Relationships to Disclose
 
Marianne Oulhen
No Relationships to Disclose
 
Isabelle Borget
No Relationships to Disclose
 
Kirsty Ross
No Relationships to Disclose
 
Nathalie Auger
No Relationships to Disclose
 
Fanny Billiot
No Relationships to Disclose
 
Maud Ngocamus
No Relationships to Disclose
 
David Planchard
Research Funding - Novartis (Inst)
 
Jean-Charles Soria
Honoraria - AstraZeneca/MedImmune; Merus; MSD Oncology; Pfizer; Roche/Genentech; Symphony Evolution
 
Francoise Farace
No Relationships to Disclose
 
Benjamin Besse
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Lilly (Inst); Onxeo (Inst); ose pharma (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Novartis; Pfizer; Pierre Fabre; Roche